11-November-2026
On 10 November, the Competition Commission of India cleared Rasmalai Limited’s proposed acquisition of a stake in Yatharth Hospital & Trauma Care Services. Yatharth had previously announced ₹3,150 crore of primary capital from Advent International, which is expected to hold about 24.9% after completion. Primary capital would go into the company. Competition clearance does not establish that the transaction has closed or that the money has been deployed.
The Pharma Times asks: Which investments will shorten the journey to specialist care? Will the money go towards new hospitals, equipment, staffing or acquisitions? And when a patient needs treatment, will the hospital be able to explain the likely bill and the insurance or public-scheme coverage before admission?
The Pharma Times recommends that the board publish a clear account of how the capital is used after closing, alongside measures patients can judge: waiting times for selected services, access under public schemes where applicable, and the accuracy of upfront cost estimates. A hospital investor should be able to explain how the investment improves access as clearly as it explains how it grows revenue.
The most convincing return on hospital investment is better care that patients can reach and afford.
